home / stock / cere / cere short
Short Information | Ceres Inc. (NASDAQ:CERE)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 3,563,498 |
Total Actual Volume | 21,102,654 |
Short Trends | |
---|---|
Cover Days | 20 |
Short Days | 0 |
No Change Days | 0 |
Averages | |
---|---|
Average Short Volume | 178,175 |
Average Short Percentage | 16.43% |
Is there a CERE Short Squeeze or Breakout about to happen?
See the CERE Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
05-01-2024 | $42.73 | $42.63 | $42.86 | $42.6 | 931,485 | 79,717 | 8.56% |
04-30-2024 | $42.57 | $42.71 | $42.82 | $42.56 | 1,059,658 | 161,177 | 15.21% |
04-29-2024 | $42.49 | $42.75 | $42.845 | $42.38 | 714,167 | 126,831 | 17.76% |
04-26-2024 | $42.02 | $42.47 | $42.491 | $41.93 | 680,906 | 110,784 | 16.27% |
04-25-2024 | $41.81 | $42.07 | $42.185 | $41.8 | 691,659 | 66,372 | 9.6% |
04-24-2024 | $41.97 | $41.9 | $42.06 | $41.87 | 629,646 | 86,784 | 13.78% |
04-23-2024 | $42.1 | $41.99 | $42.14 | $41.9 | 1,389,982 | 324,577 | 23.35% |
04-22-2024 | $42.28 | $42.1 | $42.3 | $41.86 | 701,473 | 58,563 | 8.35% |
04-19-2024 | $42.01 | $42.21 | $42.23 | $42 | 813,324 | 164,998 | 20.29% |
04-18-2024 | $41.88 | $42.14 | $42.21 | $41.7 | 1,282,830 | 251,640 | 19.62% |
04-17-2024 | $41.47 | $41.6 | $41.8 | $41.3 | 838,023 | 120,573 | 14.39% |
04-16-2024 | $41.6 | $41.31 | $41.805 | $41.185 | 1,439,526 | 200,421 | 13.92% |
04-15-2024 | $41.83 | $41.7 | $41.92 | $41.535 | 1,333,538 | 223,398 | 16.75% |
04-12-2024 | $42.02 | $41.85 | $42.045 | $41.5 | 2,259,340 | 419,890 | 18.58% |
04-11-2024 | $42.17 | $42.01 | $42.18 | $42 | 948,569 | 157,338 | 16.59% |
04-10-2024 | $42.1 | $42.11 | $42.2706 | $42.04 | 1,218,905 | 184,960 | 15.17% |
04-09-2024 | $42.2 | $42.13 | $42.2 | $42.035 | 748,979 | 199,314 | 26.61% |
04-08-2024 | $42.17 | $42.21 | $42.28 | $42.1 | 1,057,738 | 178,610 | 16.89% |
04-05-2024 | $42.15 | $42.17 | $42.28 | $42.04 | 976,840 | 151,895 | 15.55% |
04-04-2024 | $42.31 | $42.17 | $42.405 | $42.155 | 1,386,066 | 295,656 | 21.33% |
News, Short Squeeze, Breakout and More Instantly...
Enact Holdings Inc. (ACT) is expected to report $0.99 for Q1 2024 FormFactor Inc. (FORM) is expected to report $0.09 for Q1 2024 SAAB AB - Class B (SAABF) is expected to report for quarter end 2024-03-31 Lumos Pharma Inc. (LUMO) is expected to report $-1.21 for Q1 2024 Axis Capita...
On Thursday, Cerevel Therapeutics Holdings Inc. (NASDAQ:CERE) released topline results from its pivotal Phase 3 TEMPO-3 trial for tavapad...
Tavapadon met the primary endpoint in the pivotal Phase 3 TEMPO-3 adjunctive trial, demonstrating a statistically significant increase in total “on” time without troublesome dyskinesia compared with placebo over 27 weeks Results demonstrate tavapadon’s potential to ...